Subscribe To

Price Alert Latest News Economic Calendar News

ATXS / Astria Therapeutics to Present STAR-0215 at the 13th C1-Inhibitor Deficiency and Angioedema Workshop

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information on STAR-0215 and its development in two presentations at the 13th C1-Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary. Jou-Ku Chung, Vice President, Clinical Pharmacology and Trans. Read More

Demo Live Account See Partner Details

Content Topics

Astria

Therapeutics

Present

Star

0215

13th

C1

Inhibitor

Star 0215

C1 inhibitor

Deficiency

Angioedema

Workshop

Stock

ATXS

Posted: Apr 28 2023, 08:00

Author Name: Business Wire

ATXS News

By Business Wire
November 3, 2023

Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allerg

By Proactive Investors
October 12, 2023

Astria Therapeutics strikes exclusive license agreement for dermatitis treatment portfolio

Astria Therapeutics has inked a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio targeting the potential treatment of

By Zacks Investment Research
July 21, 2023

Astria (ATXS) Rises 5% on Fast Track Tag for Angioedema Drug

Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to t

By Business Wire
April 28, 2023

Astria Therapeutics to Present STAR-0215 at the 13th C1-Inhibitor Deficiency and Angioedema Workshop

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary ang

By Seeking Alpha
April 24, 2023

Astria: Biotech To Watch With Proof Of Concept Established For HAE

Astria: Biotech To Watch With Proof Of Concept Established For HAE.

By Zacks Investment Research
December 27, 2022

What Makes Astria Therapeutics, Inc. (ATXS) a Good Fit for 'Trend Investing'

If you are looking for stocks that are well positioned to maintain their recent uptrend, Astria Therapeutics, Inc. (ATXS) could be a great choice. It

By Seeking Alpha
December 24, 2022

Astria Therapeutics: Tailwinds Building With Novel Treatment Paradigm

ATXS has broken out from a 37-week price reversal. Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of swelling in

By Business Wire
March 9, 2022

Astria Therapeutics to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary ang

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.